A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome
Phase: PHASE1
Conditions: Alport Syndrome
Sponsor: Calliditas Therapeutics AB



PPD
PPD
PPD
PPD
PPD
PPD

PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD